<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00156884</url>
  </required_header>
  <id_info>
    <org_study_id>GUPPS2</org_study_id>
    <nct_id>NCT00156884</nct_id>
  </id_info>
  <brief_title>A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer</brief_title>
  <official_title>A Randomized Phase II Trial of Strontium-89 With or Without Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alberta Health Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Prostate Cancer Research Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amersham Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <brief_summary>
    <textblock>
      This study is designed to determine whether the combination of low dose cisplatin and
      strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in
      hormone refractory prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to determine whether the combination of low dose cisplatin and
      strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in
      hormone refractory prostate cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Palliative pain response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>analgesic response</measure>
  </primary_outcome>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Hormone Refractory Prostate Cancer</condition>
  <condition>Bone Metastases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>strontium-89</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adenocarcinoma of the prostate

          -  life expectancy &gt; 3 months,

          -  symptomatic from bone metastases

          -  radiologic evidence of metastatic bone disease

          -  stable level of pain control

          -  &gt;18 years

          -  ability to complete assessments

          -  prior treatment (chemo) &gt; 4 weeks previous

          -  discontinued anti-androgens for &gt; 4 weeks

        Exclusion Criteria:

          -  prior strontium therapy

          -  previous hemibody RT within 6 weeks

          -  previous cytotoxic chemotherapy within 4 weeks

          -  use of bisphosphonate medications within 4 weeks

          -  change in steroid dose within 4 weeks

          -  active uncontrolled infection

          -  impending or present spinal cord compression

          -  significant neurological disorder

          -  impending pathological fracture

          -  severe urinary incontinence
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernie Eigl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alberta Cancerboard</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jackson Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alberta Cancerboard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <keyword>prostate cancer</keyword>
  <keyword>cisplatin</keyword>
  <keyword>strontium-89</keyword>
  <keyword>phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

